SARC Biannual Meeting
November 13, 2008
AGENDA

 

Thursday, November 13, 2008

8:00 – 8:15

 Welcome/SARC Update

Laurence Baker
Chair, SARC Board of Directors  

8:15 – 8:45

 Chawla/Rosenfeld Developmental Therapeutics Symposium (Part 1)

 
  Laboratory Investigation of Resistant GIST Jonathan Fletcher

8:45– 10:15

 Review of Ongoing SARC Trials

 
 
  • SARC 003 Phase 2 Gemcitabine/Docetaxel in Bone Sarcoma

Elizabeth Fox

 
  • SARC 004 Phase 2 Neoadjuvant Imatinib in DFSP

Scott Schuetze
 
  • SARC 005 Phase 2 Adjuvant Therapy High Risk Uterine Leiomyosarcoma
 Martee L. Hensley
 
  • SARC 006 Phase 2 MPNST: Sporadic versus NF1 associated

Lee Helman
 
  • SARC 007 Phase 2 Perifosine in chemoinsensitive sarcoma

Jonathan Trent
 
  • SARC 009 Phase 2 Dasatinib in metastatic sarcoma

Scott Schuetze
 
  • SARC 011 Phase 2 IGF-1R in selected sarcomas

Alberto Pappo
 
  • SARC011 Companion Biology Protocol

Lee Helman
 
  • SARC 012 Phase 2 Src kinase Inhibitor Recurrent Osteosarcoma Localized to Lung

Lee Helman
Su Kim*
10:15—10:45 Chawla/Rosenfeld Developmental Therapeutics Symposium (Part 2)   

 

 New Approaches to GIST               

Meg von Mehren
10:45– 11:15

Review of Pending Trials

 
 

Herbert Jürgens*
Paul Meyers
Shreyas Patel

 

Richard Gorlick
 
  • SARC015 Phase 2 IGF-1R in WT GIST

Meg von Mehren
Katie Janeway*
 

Lee Helman
 
  • SARC018 Phase 2  Desmoid Surgery/Radiation

Robert Benjamin
 

 

 
11:15 – 11:30

SARC Restructuring

 
 
  • Participating Committee

Suzanne George
 

Denise Reinke

11:30-12:00

Closed Session:  SARC Business Update
(SARC Participants Only)

 
     
  * Presenter